XBiotech Inc.
NASDAQ Global SelectTotal Valuation
XBiotech Inc. carries a market capitalization of 68.29M, placing it among publicly traded companies globally. Its enterprise value stands at -43.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 68.29M |
| Enterprise Value | -43.81M |
Share Statistics
XBiotech Inc. currently has 30.49M shares outstanding.
| Shares Outstanding | 30.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | -1.71 |
| P/OCF Ratio | -1.70 |
Financial Position
XBiotech Inc. maintains a current ratio of 39.03, meaning it holds 39.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 39.03 |
| Quick Ratio | 38.60 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -25.93 |
| Return on Assets (ROA) | -24.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 255,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
XBiotech Inc.'s stock has declined approximately -24.0678% over the past 52 weeks. The 50-day moving average sits at 2.37, while the 200-day moving average is 2.43.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.0678% |
| 50-Day Moving Average | 2.37 |
| 200-Day Moving Average | 2.43 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -46.84M, while operating income came in at -48.41M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -48.41M |
| Pretax Income | -39.91M |
| Net Income | -40.16M |
| EBITDA | -46.84M |
| EBIT | -48.41M |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
Total book value stands at 135.02M, with working capital of 114.05M providing operational flexibility.
| Cash & Cash Equivalents | 115.46M |
| Total Debt | N/A |
| Net Debt | -115.46M |
| Equity (Book Value) | 135.02M |
| Book Value Per Share | 4.43 |
| Working Capital | 114.05M |
Cash Flow
XBiotech Inc. produced -42.17M in operating cash flow over the past twelve months. After subtracting -195,000.00 in capital expenditures, free cash flow totaled -42.36M - equivalent to -1.39 per share.
| Operating Cash Flow | -42.17M |
| Capital Expenditures | -195,000.00 |
| Free Cash Flow | -42.36M |
| FCF Per Share | -1.39 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -58.59 |
Scores
XBiotech Inc. posts an Altman Z-Score of 7.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.34 |